FDA COVID-19 Booster Shot Update

On Wednesday September 22, 2021, the FDA approved an amendment to the Emergency Use Authorization for the Pfizer vaccine, allowing for a booster dose for certain populations.


The CDC met on Thursday September 23, 2021 to review this recommendation. Based on the outcome of these meetings and the final review by the CDC director, the following populations are now eligible to receive a booster dose or be considered for a booster dose of the Pfizer vaccine:


  • Those over 65 years old and those who live in long-term care facilities should receive the booster 6 months after completion of the Pfizer-BioNTech two-dose primary series.

  • Those 50-64 years old who are at high risk for severe COVID-19 should receive the booster 6 months after completion of the Pfizer-BioNTech two-dose primary series.

  • Those 18-49 years old who have certain high risk medical conditions may be considered for the booster based on individual benefits and risk, starting 6 months after completion of the Pfizer-BioNTech two-dose primary series.

  • Those 18-64 whose institutional or occupational exposure to COVID-19 puts them at risk of serious complications from COVID-19, including severe COVID-19, may be considered for the booster based on individual benefits and risk, starting 6 months after completion of the Pfizer-BioNTech two-dose primary series.


This booster dose is to be given at least 6 months from the second shot.


The booster dose is only for those who had the Pfizer vaccine.


If you have any questions regarding the newest FDA and CDC update or believe you are eligible for this booster shot, please send a portal message to your provider or call our office at 978-774-2555. A telemedicine visit may be required so our providers can review your chart and discuss concerns and eligibility status. Please be aware that we will need a copy of your vaccine card prior to scheduling your booster dose.